# EDGAR Filing Document

**Accession Number:** 0001757499
**File Stem:** 0000000000-26-000682
**Filing Date:** 2026-1
**Character Count:** 3179
**Document Hash:** bd8fb8884a9bfb54898cbd277985d39f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-26-000682.hdr.sgml**: 20260319

**ACCESSION NUMBER**: 0000000000-26-000682

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260116

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Shuttle Pharmaceuticals Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001757499
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-291628

**BUSINESS ADDRESS:**
- **STREET 1:** 401 PROFESSIONAL DRIVE
- **STREET 2:** SUITE 260
- **CITY:** GAITHERSBURG
- **STATE:** MD
- **ZIP:** 20879
- **BUSINESS PHONE:** (240) 403-4212

**MAIL ADDRESS:**
- **STREET 1:** 401 PROFESSIONAL DRIVE
- **STREET 2:** SUITE 260
- **CITY:** GAITHERSBURG
- **STATE:** MD
- **ZIP:** 20879
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001493152-25-024089

## Text-Extract

```

                                                              January 16, 2026

Christopher Cooper
Interim Chief Executive Officer
Shuttle Pharmaceuticals Holdings, Inc.
401 Professional Drive, Suite 260
Gaithersburg, MD 20879

       Re: Shuttle Pharmaceuticals Holdings, Inc.
           Registration Statement on Form S-1
           Response dated December 29, 2025
           File No. 333-291628
Dear Christopher Cooper:

        We have reviewed your December 29, 2025 response to our comment letter
and have
the following comment. If you do not believe our comment applies to your facts
and
circumstances, please tell us why in your response.

       After reviewing your response to this letter, we may have additional
comments.

Response dated December 29, 2025
General

1.     We note your response to our prior comment. Please provide us with the
following
       information:

             Tell us how you will account for the acquisition.
             Your disclosure says that you acquired substantially all of the
assets and liabilities
           of Molecule.ai. Please confirm whether you acquired the legal entity
of
           Molecule.ai.
             Please confirm whether the software platform you acquired was
ready to use upon
           acquisition.
             Please describe any arrangements you have with Zhitian (Andy)
Zhang to provide
           post-acquisition services to your company.
             Please provide an estimate of the additional development costs you
expect to be
           incurred on the software platform post-acquisition compared to the
costs incurred
           prior to acquisition.
 January 16, 2026
Page 2

       Please contact Alan Campbell at 202-551-4224 or Laura Crotty at
202-551-7614 with
any questions.

                                                        Sincerely,

                                                        Division of Corporation
Finance
                                                        Office of Life Sciences
cc:   Aaron M. Schleicher, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._